Production (Stage)
Barinthus Biotherapeutics plc
BRNS
$0.654
-$0.156-19.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -65.23M | -61.07M | -57.83M | -63.79M | -70.66M |
| Total Depreciation and Amortization | 3.20M | 2.60M | 2.61M | 2.61M | 2.44M |
| Total Amortization of Deferred Charges | 3.20M | 3.20M | 3.20M | 3.20M | 3.20M |
| Total Other Non-Cash Items | 25.63M | 23.73M | 13.82M | 3.24M | 6.24M |
| Change in Net Operating Assets | 1.18M | 2.60M | -23.43M | 116.00K | -798.00K |
| Cash from Operations | -32.02M | -28.94M | -61.63M | -54.62M | -59.57M |
| Capital Expenditure | -589.00K | -892.00K | -461.00K | -383.00K | -3.21M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -589.00K | -892.00K | -461.00K | -383.00K | -3.21M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.66M | 2.16M | 1.44M | 1.02M | 749.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | 0.00 | -63.00K |
| Cash from Financing | 1.66M | 2.16M | 1.44M | 1.02M | 686.00K |
| Foreign Exchange rate Adjustments | 1.56M | -2.02M | 6.45M | -1.27M | 744.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -29.39M | -29.69M | -54.21M | -55.26M | -61.36M |